N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial.
Sarris J, Byrne G, Castle D, Bousman C, Oliver G, Cribb L, Blair-West S, Brakoulias V, Camfield D, Ee C, Chamoli S, Boschen M, Dean OM, Dowling N, Menon R, Murphy J, Metri NJ, Nguyen TP, Wong A, Jordan R, Karamacoska D, Rossell SL, Berk M, Ng CH.
Sarris J, et al. Among authors: blair west s.
Prog Neuropsychopharmacol Biol Psychiatry. 2022 Jul 13;117:110550. doi: 10.1016/j.pnpbp.2022.110550. Epub 2022 Mar 15.
Prog Neuropsychopharmacol Biol Psychiatry. 2022.
PMID: 35304155
Clinical Trial.